-
Mountain-made: Balkan sheepdog eyes future beyond the hills
-
Escaped wolf forces school closure in South Korea
-
Three ways Orban gives himself an edge in Hungary's vote
-
Trump says US military to stay deployed near Iran until 'real agreement' reached
-
Gender-row boxer Lin targets Asian Games after bronze on comeback
-
US-Iran truce shows cracks as war flares in Lebanon
-
In Romania, many Hungarians root for Orban in vote
-
Home where young Bowie dreamt of 'fame' to open to public
-
Crude rises, stocks fall on fears over nascent Iran ceasefire
-
Waiting for DeepSeek: new model to test China's AI ambitions
-
You're being watched: Japan battles online abuse of athletes
-
US court expedites Anthropic's legal battle with Department of War
-
Badminton to trial synthetic shuttlecocks because of feather shortage
-
Firm, fast Augusta set to test golf's best in 90th Masters
-
BTS to kick off world tour after landmark Seoul comeback
-
Grand National had to change to survive, says former winning jockey
-
Maple syrup or nutella? PM Carney calls Canadian Artemis astronaut
-
Comedy duo Flight of the Conchords reunion gigs sell out in minutes
-
US-Iran truce enters second day as war flares in Lebanon
-
Trump blasts NATO after closed-door Rutte meeting
-
Houston, we have a problem ... with the toilet
-
Slot admits Liverpool in 'survival mode' in PSG defeat
-
Trump makes up with Sahel juntas, with eye on US interests
-
Tiger Woods drug records to be subpoenaed by prosecutors
-
England's Rai wins Par-3 Contest to risk Masters curse
-
Brazil's Chief Raoni backs Lula in elections
-
Trump to discuss leaving NATO in meeting with Rutte
-
Atletico punish 10-man Barcelona, take control of Champions League tie
-
Dominant PSG leave Liverpool right up against it in Champions League tie
-
Meta releases first new AI model since shaking up team
-
Tehran residents relieved but divided by Trump truce
-
Vance says up to Iran if it wants truce to 'fall apart' over Lebanon
-
US, Iran truce hangs in balance as war flares in Lebanon
-
Scale of killing in Lebanon 'horrific': UN rights chief
-
'Ketamine Queen' jailed for 15 years over Matthew Perry drugs
-
Betis earn draw in Europa League quarter-final at Braga
-
Buttler hits form with IPL fifty as Gujarat win last-ball thriller
-
'Total victory' or TACO? Trump faces questions on Iran deal
-
Medvedev thrashed at Monte Carlo as Zverev battles through
-
Trump to discuss leaving NATO in meeting with Rutte: White House
-
Five US multiple major champions seek first Masters win
-
Howell got McIlroy ball as kid and now joins him at Masters
-
Turkey puts 11 on trial for LGBT 'obscenity'
-
Augusta boss eyes tradition and innovation balance at Masters
-
In Trump war on Iran, tactical wins and long-term damage to US
-
Argentine MPs to debate watered-down glaciers protection
-
Brazilian police dog sniffs out 48 tons of marijuana in record bust
-
Leicester close to third tier after points deduction appeal dismissed
-
In the heart of Beirut, buildings in flames and charred cars
-
Dilemma over crossings as fate of Hormuz ships remains uncertain
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA / ACCESS Newswire / January 12, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced that on January 8, 2026, the Compensation Committee of Revelation's Board of Directors approved an inducement grant consisting of 90,000 restricted stock units ("RSUs") covering 90,000 shares of the Company's common stock to a new non-executive employee. The RSUs were granted outside of the Company's stockholder-approved equity incentive plan. The award was granted as an inducement material to the employee's acceptance of employment with Revelation in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over two years in equal quarterly installments, beginning on the first quarterly vesting date following the employee's new hire date, subject to the employee's continued service with the Company through the vesting dates.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of chronic kidney disease, prevention for post-surgical infection and as a treatment for acute kidney injury.
For more information on Revelation, please visit www.RevBiosciences.com.
Company Contact
Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: [email protected]
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: [email protected]
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
D.Lopez--AT